Nano or micro structure and its manufacturing method

Abstract

Provided is a nanostructure or a microstructure comprising a plurality of cyclic molecules, each of which is provided with an opening, and a plurality of chain-like molecules, the nanostructure or microstructure being such that each of the plurality of chain-like molecules is included in skewered fashion in some of the plurality of cyclic molecules, whereby a plurality of pseudo-polyrotaxanes and / or polyrotaxanes are formed, wherein some or all of the adjacent cyclic molecules in the nanostructure or microstructure crosslink with each other.

Description

[Technical Field]

[0001] The present invention relates to a nano- or microstructure having a plurality of pseudopolyrotaxanes and / or polyrotaxanes, and a method for producing the same. [Background technology]

[0002] Cyclodextrins have a ring structure, and the inside is hydrophobic, allowing them to incorporate hydrophobic molecules (guest molecules) into the interior in water. In many cases, after incorporating the hydrophobic molecules, strong hydrogen bonds are formed between the hydroxyl groups in the cyclodextrin, causing spontaneous crystallization, at which point the cyclodextrin forms single crystals on the order of micrometers. The shape and size (crystal habit) of the single crystals can be altered by controlling the type and structure of the polymer that serves as the guest molecule and the crystal growth process.

[0003] The inventors previously invented nanosheets having multiple pseudopolyrotaxanes and / or polyrotaxanes in which linear molecules skewer through the openings of cyclic molecules and are encapsulated by the cyclic molecules, as well as a method for producing the same (Patent Documents 1 and 2). These nanosheets have relatively simple synthesis and film-forming processes, and are highly biosafe and compatible, making them promising for application in a variety of technical fields, including pharmaceuticals and biomaterials. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] WO2020 / 013215 [Patent Document 2] WO2020 / 175679 Summary of the Invention [Problem to be solved by the invention]

[0005] However, in the isolated nanosheets described in Patent Documents 1 and 2, the cyclic molecules arranged on the chain molecules in each pseudopolyrotaxane and / or polyrotaxane can move along the chain molecules at a low inclusion rate, which can lead to the decomposition of the isolated nanosheets when diluted in certain solvents. Furthermore, in the isolated nanosheets described in Patent Documents 1 and 2, multiple cyclic molecules are arranged in a manner such that the openings of each cyclic molecule are pierced by chain molecules in a skewered manner. Because the chain molecules are present in the openings of the cyclic molecules, the proportion of space within the openings of the cyclic molecules that can be used for supporting substances, such as adsorption or inclusion of external substances, is low. It is desirable to solve at least one of these problems. [Means for solving the problem]

[0006] The present invention encompasses the embodiments described below. Item 1. A nano- or microstructure comprising a plurality of cyclic molecules each having an opening and a plurality of chain molecules, wherein each of the plurality of chain molecules is skewered and included in some of the plurality of cyclic molecules to form a plurality of pseudo-polyrotaxanes and / or polyrotaxanes, A nano- or microstructure in which all or some of the adjacent cyclic molecules in the nano- or microstructure are crosslinked to each other. Item 2. A nano- or microstructure according to Item 1, wherein 50% or more of the total number of cyclic molecules in the nano- or microstructure are crosslinked. Item 3. A nano- or microstructure according to Item 1 or 2, wherein the plurality of cyclic molecules arranged in series in the nano- or microstructure form columns, and the number of columns that do not include chain molecules exceeds 10% of the total number of columns in the nano- or microstructure. Item 4. The nano- or microstructure according to any one of Items 1 to 3, wherein each of the chain molecules in the plurality of pseudopolyrotaxanes and / or polyrotaxanes has a non-ionizable group at or near both ends that does not ionize in water or an aqueous solution. Item 5. The nano- or microstructure according to any one of Items 1 to 3, wherein each of the chain molecules in the plurality of pseudopolyrotaxanes and / or polyrotaxanes has an ionizable group at or near both ends that is ionized under conditions for fabricating a nano- or microstructure. Item 6. The nano- or microstructure according to any one of Items 1 to 5, wherein the chain molecule has first and second regions inward from both ends of the chain molecule where the cyclic molecule is not present, and the lengths of the first and second regions are 0.5 to 100 nm. Item 7. The nano- or microstructure according to any one of Items 1 to 6, wherein the cyclic molecule is selected from the group consisting of α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, crown ether, pillararene, calixarene, cyclophane, cucurbituril, and derivatives thereof. Item 8. The nano- or microstructure according to any one of Items 1 to 7, wherein a substance is enclosed in the openings. Item 9. The nano- or microstructure according to any one of Items 1 to 8, wherein the microstructure is a nanosheet. Item 10. An adsorbent for a substance comprising the nano- or microstructure according to any one of items 1 to 9. Item 11. A pharmaceutical comprising the nano- or microstructure according to any one of items 1 to 9. Item 12. A pharmaceutical comprising the nano- or microstructure according to any one of items 1 to 9. Item 13. A method for producing a nano- or micro-structure, A method comprising the step of crosslinking a nano- or microstructure comprising a plurality of pseudo-polyrotaxanes and / or polyrotaxanes each comprising a plurality of cyclic molecules each having an opening and a plurality of chain molecules, each of the plurality of chain molecules being skewered and included in some of the plurality of cyclic molecules, to obtain a nano- or microstructure in which all or some of adjacent cyclic molecules are crosslinked to each other. Item 14. The method according to Item 13, further comprising the step of removing some or all of the chain molecules that are skewered and included in some of the cyclic molecules. [Effects of the Invention]

[0007] According to the present invention, the cyclic molecules in the nano- or microstructure are more strongly bonded to each other, making the nano- or microstructure less susceptible to decomposition. [Brief explanation of the drawings]

[0008] [Figure 1] 1A-1E are schematic diagrams showing a method for producing nanosheets according to an embodiment of the present invention. [Figure 2] 1 is a schematic perspective view of a nano- or microstructure according to another embodiment of the present invention; [Figure 3] Schematic diagram showing the relationship between molecular weight of linear polymers and the shape of the structure. (A) Example of rod-shaped structures produced when PEO is short chain, (B) Example of cube-shaped structures produced when PEO is longer than (A), (C) Example of sheet-shaped structures produced when PEO is even longer than (B), and (D) Example of sheet-shaped structures produced when PEO is even longer than (C). [Figure 4] (A) Branched PEO, (B) Schematic diagram of a sheet of a structure using the branched PEO of (A), (C) Schematic diagram showing the connection state of the sheet of (B). [Figure 5] (A)-(F) Diagrams showing the relationship between the order of chemical bonding of γ-CD to segments of different compositions in the linear polymer and the shape of the structure. (A) Tripolymer with three segments, each consisting of a central PPO segment and two 0.2K PEO segments. (B) Tripolymer with three segments, each consisting of a central PPO segment and two 1.1K PEO segments. (C) Tripolymer with three segments, each consisting of a central PPO segment and two 6.5K PEO segments. (D) Schematic of the structure formed using the linear polymer in Figure 5(A) (left) with an enlarged view of the circled area (right). (E) Schematic of the structure formed using the linear polymer in Figure 5(B) (left) with an enlarged view of the circled area (right). (F) Schematic of the structure formed using the linear polymer in Figure 5(C) (left) with an enlarged view of the circled area (right). [Figure 6](A) Schematic front view of a pseudo-polyrotaxane in which the linear polymer is polypropylene oxide (PPO), (B) Schematic front view of a pseudo-polyrotaxane in which the linear polymer is polyethylene oxide (PEO), (C) Schematic front view of a pseudo-polyrotaxane in which the linear polymer extends from one end of a column consisting of a series of cyclic molecules to the other, (D) Schematic front view of a pseudo-polyrotaxane in which the linear polymer extends beyond the bottom end of a column consisting of six cyclic molecules but not all the way to the top end, (E) Schematic front view of a pseudo-polyrotaxane in which the linear polymer does not reach the top or bottom end of a column consisting of six cyclic molecules, and (F) Schematic front view showing a series of cyclic molecules without a linear polymer. [Figure 7] A photograph of a solution of IT-162 nanosheet-containing sample diluted with water, observed under a phase-contrast microscope. [Figure 8] Scanning microscope image of the crystal structure in sample IT-162. [Figure 9] Atomic force microscope image and graph (inset) of the crystalline structure in sample IT-162. [Figure 10] (A) Phase contrast and (B) fluorescence micrographs of the diluted solution of Example 3. [Figure 11] (A) Phase contrast microscope photograph and (B) fluorescence microscope photograph of the diluted solution of Comparative Example 2. DETAILED DESCRIPTION OF THE INVENTION

[0009] Hereinafter, an embodiment of the present invention will be described.

[0010] According to an embodiment of the present invention, there is provided a nano- or microstructure comprising a plurality of cyclic molecules each having an opening and a plurality of chain molecules, wherein each of the plurality of chain molecules is skewered and enclosed by a corresponding part of the plurality of cyclic molecules to form a plurality of pseudo-polyrotaxanes and / or polyrotaxanes, and wherein all or some of adjacent cyclic molecules in the nano- or microstructure are cross-linked to each other.

[0011] As used herein, the term "nano- or microstructure" refers to a "nanostructure or microstructure." A "nanostructure" refers to a structure in which the dimension along at least one of the a-axis, b-axis, and c-axis of the structure's crystal is 1 nm or more, and the dimensions along all of the a-axis, b-axis, and c-axis of the structure's crystal are less than 1 μm. A "microstructure" refers to a structure in which the dimension along at least one of the a-axis, b-axis, and c-axis of the structure's crystal is 1 μm or more.

[0012] Furthermore, in this specification, the term "nanosheet" refers to a sheet-like nano- or microstructure in which the thickness of a single layer of the nanosheet is less than 100 nm, preferably 1 to 100 nm, more preferably 3 to 50 nm, and even more preferably 5 to 20 nm. When the nanosheet is composed of multiple layers, the thickness of the single nanosheets that make up the nanosheets is 100 nm or less, preferably 1 to 100 nm, more preferably 3 to 50 nm, and even more preferably 5 to 20 nm. A nanosheet is a nanostructure when the dimensions along all of the crystal a-axis, b-axis, and c-axis are less than 1 μm, and is a microstructure when the dimension along at least one of the crystal a-axis, b-axis, and c-axis of the structure is 1 μm or more.

[0013] The thickness direction of the nanosheet consisting of a single layer is preferably the longitudinal direction of the pseudopolyrotaxane and / or polyrotaxane, in other words, the longitudinal direction of the chain molecules.The longitudinal direction of the pseudopolyrotaxane and / or polyrotaxane and the longitudinal direction of the chain molecules are preferably the thickness direction of the isolated nanosheet consisting of a single layer of the present invention.

[0014] The nano- or microstructure of an embodiment of the present invention may be an isolated nano- or microstructure. In particular, the nanosheet may be an isolated nanosheet. As used herein, the term "isolated" in "isolated nano- or microstructure" and "isolated nanosheet" refers to the ability to exist independently in solution without aggregation. An "isolated nano- or microstructure" may consist of a single layer or multiple layers, and an "isolated nanosheet" may consist of a single layer or multiple layers. The formation of an isolated nano- or microstructure can be confirmed by small-angle X-ray scattering, phase-contrast optical microscopy, atomic force microscopy, or scanning electron microscopy. In particular, an isolated nanosheet can be confirmed as an isolated nanosheet by small-angle X-ray scattering when its shape factor shows a sheet-like shape, specifically, when the shape factor exhibits fringes characteristic of a sheet structure and no increase in scattering intensity due to aggregation is observed at the base angle (see, for example, Principles and Applications of X-ray, Light, and Neutron Scattering (KS Chemistry Specialist)).

[0015] In this specification, a "polyrotaxane" refers to a chain molecule having groups (blocking groups) at both ends thereof that have a blocking effect (blocking action) to prevent the cyclic molecule to be included from being released from the inclusion state, whereas a "pseudopolyrotaxane" refers to a chain molecule having a group (blocking group) with the above blocking effect at only one end thereof, or having no groups (blocking groups) with the above blocking effect at both ends thereof.

[0016] In this specification, a nano- or microstructure having a plurality of "pseudopolyrotaxanes and / or polyrotaxanes" means a case where only "pseudopolyrotaxanes" are present, a case where only "polyrotaxanes" are present, or a case where at least one type of "pseudopolyrotaxane" and at least one type of "polyrotaxane" are present, and the total number of "pseudopolyrotaxanes" and "polyrotaxanes" is a plurality.

[0017] Examples of cyclic molecules include, but are not limited to, α-cyclodextrin (hereinafter, in this specification, "cyclodextrin" may be simply referred to as "CD"), β-cyclodextrin, γ-cyclodextrin, crown ether, pillararene, calixarene, cyclophane, cucurbituril, and derivatives thereof. From the viewpoint of ease of sheet production and application, α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin are preferred. Examples of derivatives include, but are not limited to, methylated α-cyclodextrin, methylated β-cyclodextrin, methylated γ-cyclodextrin, hydroxypropylated α-cyclodextrin, hydroxypropylated β-cyclodextrin, and hydroxypropylated γ-cyclodextrin. One nano- or microstructure may contain one or more types of cyclic molecules.

[0018] The pseudopolyrotaxane and / or chain molecules constituting the polyrotaxane forming the nano- or microstructure preferably have first and second regions (hereinafter sometimes simply referred to as "cyclic molecule-free regions") inward from both ends of the chain where no cyclic molecules are present. That is, the first region is present inward from one end of the first chain molecule, and the second region is present inward from the other end of the first chain molecule.

[0019] The lengths of the first and second regions are each independently 0.5 to 100 nm, preferably 1 to 70 nm, and more preferably 1 to 50 nm. While not based on a complete theory, it is believed that having a "cyclic molecule-free region" of the above length is particularly advantageous for the formation of isolated nanosheets. The thickness of the nanosheet and the length of the chain molecules can be determined by small-angle X-ray scattering or atomic force microscopy.

[0020] The chain molecule may be a straight chain, i.e., a single chain, or may be a branched chain. Preferred branched chains include tri-branched chains (one branch point) and tetra-branched chains (two branch points).

[0021] The chain molecule may be a polymer whose entire structure is a repeating structure of the same monomer, or may be a block copolymer having at least two blocks, or may be a block copolymer having at least three blocks.

[0022] Each block of the "block copolymer" preferably consists of only one repeating unit, but may have a first spacer group between one repeating unit and the next repeating unit.

[0023] There may also be a second spacer group between adjacent blocks of the "block copolymer", which may be the same as or different from the first spacer group.

[0024] Examples of the first and / or second spacer group include, but are not limited to, linear or branched alkyl groups having 1 to 20 carbon atoms, such as methylene, ethylene, propylene, butylene, and pentylene groups (which may be partially substituted with an aromatic ring such as a phenyl group); linear or branched ethers having 1 to 20 carbon atoms; linear or branched esters having 1 to 20 carbon atoms; and aromatic groups having 6 to 24 carbon atoms, such as a phenyl group.

[0025] The cyclic molecule may be included in one of the at least two blocks of a chain molecule having at least two blocks, or in one of the at least three blocks (particularly the central block).

[0026] In the present application, the chain molecule is not particularly limited as long as it is a chain molecule that can be included in the cyclic molecule in a skewered manner, as described above.

[0027] Examples of the chain molecular skeleton include long-chain fatty acids having 12 or more carbon atoms, polyvinyl alcohol, polyvinylpyrrolidone, poly(meth)acrylic acid, cellulose-based resins (carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, etc.), polyacrylamide, polyethylene oxide, polyethylene glycol, polypropylene glycol, polyvinyl acetal-based resins, polyvinyl methyl ether, polyamine, polyethyleneimine, casein, gelatin, starch, etc. and / or copolymers thereof, polyolefin-based resins such as polyethylene, polypropylene, and copolymer resins with other olefin-based monomers, polyester resins, polyvinyl chloride resins, polystyrene-based resins such as polystyrene and acrylonitrile-styrene copolymer resins, polymethyl methacrylate, etc. Examples of the polymer include polymers selected from the group consisting of acrylic resins such as acrylate, (meth)acrylic acid ester copolymers, and acrylonitrile-methyl acrylate copolymer resins, polycarbonate resins, polyurethane resins, vinyl chloride-vinyl acetate copolymer resins, polyvinyl butyral resins, and derivatives or modified products thereof, polyisobutylene, polytetrahydrofuran, polyaniline, acrylonitrile-butadiene-styrene copolymers (ABS resins), polyamides such as nylon, polyimides, polyisoprene, polybutadiene, and other polysiloxanes, polydimethylsiloxane, polysulfones, polyimines, polyacetic anhydrides, polyureas, polysulfides, polyphosphazenes, polyketones, polyphenylenes, polyhaloolefins, and derivatives thereof. For example, the polymer may be selected from the group consisting of polyethylene glycol, polyisoprene, polyisobutylene, polybutadiene, polypropylene glycol, polytetrahydrofuran, polydimethylsiloxane, polyethylene, polypropylene, polyvinyl alcohol, and polyvinyl methyl ether. Polyethylene glycol and polypropylene glycol are particularly preferred. Two or more different polymers selected from these polymers may form at least two or at least three blocks.

[0028] When the chain molecule has, for example, at least two or at least three blocks, the weight-average molecular weight of the chain molecule itself is preferably 500 to 500,000, preferably 1,000 to 20,000, and more preferably 6,000 to 16,000. The weight-average molecular weight of the chain molecule can be measured by gel permeation chromatography (GPC). The measurement conditions for GPC depend on the type of chain molecule, but it is recommended to appropriately select the type of eluent and column, temperature, standard substance, and flow rate.

[0029] The chain molecule is preferably a water-soluble chain molecule. The water-soluble chain molecule is not particularly limited as long as it has the property of being water-soluble, for example, capable of dissolving 1 g in 1 L of water.

[0030] Examples of the backbone of the water-soluble chain molecule that forms at least two or at least three blocks include, but are not limited to, polyethylene glycol, polypropylene glycol, polyvinyl alcohol, polyethyleneimine, polyacrylic acid, polymethacrylic acid, polyacrylamide, pullulan, water-soluble cellulose derivatives such as hydroxypropyl cellulose, polyvinylpyrrolidone, polypeptides, and copolymers containing polyethylene glycol.

[0031] That is, the water-soluble chain molecule is at least one selected from the group consisting of the polymer species listed above, preferably at least one selected from the group consisting of polyethylene glycol, polypropylene glycol, polyvinyl alcohol, polyethyleneimine, and copolymers containing polyethylene glycol, more preferably at least one selected from the group consisting of polyethylene glycol and polypropylene glycol. For example, when the chain molecule is a water-soluble chain molecule consisting of one type of polymer, it may be a polymer consisting of only polyethylene glycol, only polypropylene glycol, only polyvinyl alcohol, only polyethyleneimine, or only polyethylene glycol. When the chain molecule is a water-soluble chain molecule consisting of three blocks, the central block may be polypropylene glycol and both sides may be polyethylene glycol.

[0032] The molecular weight (number average molecular weight or weight average molecular weight) of the water-soluble chain molecule is not particularly limited, but is preferably 500 to 500,000, preferably 1,000 to 50,000, and more preferably 2,000 to 20,000.

[0033] The pseudo-polyrotaxane and / or polyrotaxane chain molecules constituting the nano- or microstructure may be one type of chain molecule or two or more types of chain molecules, but preferably consist essentially of one type of chain molecule, and more preferably consist only of one type of chain molecule. Note that "consisting essentially of one type of chain molecule" means that other types of "chain molecules" are also present as pseudo-polyrotaxane and / or polyrotaxane chain molecules constituting the nano- or microstructure, but their presence is present to the extent that it does not adversely affect the formation of the nano- or microstructure. Furthermore, "consisting only of one type of chain molecule" means that no other types of chain molecules are present as pseudo-polyrotaxane and / or polyrotaxane chain molecules constituting the nano- or microstructure.

[0034] The inclusion rate is the proportion of cyclic molecules contained in the pseudopolyrotaxane and / or polyrotaxane, and is the proportion of the amount of chain molecules enclosed by cyclic molecules relative to the maximum amount of chain molecules enclosed by cyclic molecules (when the specified inclusion rate is 100%).

[0035] For example, if the chain molecule is polyethylene glycol (PEG) and the cyclic molecule is α-cyclodextrin, it is known that the thickness of α-cyclodextrin is equal to two repeating units of polyethylene glycol. Therefore, the specified inclusion rate is 100% when the ratio of moles of α-cyclodextrin to repeating units of polyethylene glycol is 1:2.

[0036] The inclusion ratio can be determined by small-angle X-ray scattering (SAXS) measurement of the resulting nano- or microstructure dispersion. Specifically, the inclusion ratio can be determined from the ratio of the sheet thickness, determined by fitting the one-dimensional SAXS profile of the pseudopolyrotaxane and / or polyrotaxane dispersion using an equation assuming a sheet structure, to the trans-extended chain length of the chain molecule.

[0037] In the present application, the inclusion rate of the pseudopolyrotaxane and / or polyrotaxane is 1 to 100%, preferably 5 to 100%, more preferably 10 to 100%, and most preferably 20 to 100%.

[0038] After forming a nano- or microstructure having multiple pseudopolyrotaxanes and / or polyrotaxanes as described, for example, in WO2020 / 013215 and WO2020 / 175679, adjacent cyclic molecules can be crosslinked by a known method for crosslinking cyclic molecules, such as using a crosslinking agent, to obtain a nano- or microstructure in which adjacent cyclic molecules are crosslinked to each other. Details of crosslinking of cyclic molecules will be described later in relation to the method for producing a nano- or microstructure according to an embodiment of the present invention.

[0039] For example, in the case of a nano- or microstructure in which the chain molecules are a triblock polymer of PEO-PPO-PEO (polyethylene oxide-polypropylene oxide-polyethylene oxide) and the cyclic molecules are cyclodextrin, the nano- or microstructure dissolves when diluted with water before the crosslinking reaction, but does not dissolve when diluted with water after the crosslinking reaction. Thus, crosslinking improves the stability of the nano- or microstructure against solvents. Furthermore, crosslinking of the cyclic molecules strengthens the structures within the nano- or microstructure, thereby improving the ability of the nano- or microstructure to support target molecules in its pores (the space within a column partitioned by multiple cyclic molecules, the opening partitioned by a single cyclic molecule, or the space between multiple pseudopolyrotaxanes and / or polyrotaxanes), and the surface adhesion of target molecules (substances to be adsorbed) due to the structure of the nano- or microstructure.

[0040] The proportion of crosslinked cyclic molecules to the total number of cyclic molecules in a nano- or microstructure is not particularly limited, but may be 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, or 100%. The higher the crosslinking proportion, the more effective the effects of inhibiting decomposition of the nano- or microstructure due to the structural stability of the nano- or microstructure, the function of supporting target molecules, or the surface adhesive effect.

[0041] Crosslinking of cyclic molecules in a nano- or microstructure includes adjacent crosslinking within a single plurality of pseudo-polyrotaxane and / or polyrotaxane molecules, i.e., serial crosslinking of adjacent cyclic molecules along the length direction of the chain molecules of a single plurality of pseudo-polyrotaxane and / or polyrotaxane molecules, and crosslinking between cyclic molecules within adjacent pseudo-polyrotaxane and / or polyrotaxane molecules, i.e., parallel crosslinking.

[0042] The serial crosslinking of adjacent cyclic molecules refers to adjacent cyclic molecules among the plurality of cyclic molecules in each of some or all of the plurality of pseudopolyrotaxanes and / or polyrotaxanes are crosslinked to each other.

[0043] The parallel crosslinking of cyclic molecules in adjacent pseudo-polyrotaxanes and / or polyrotaxane molecules refers to the crosslinking of cyclic molecules in some or all of the adjacent pseudo-polyrotaxanes and / or polyrotaxanes among a plurality of pseudo-polyrotaxanes and / or polyrotaxanes.

[0044] In some embodiments, crosslinking of cyclic molecules in the nano- or microstructure comprises serial crosslinking of adjacent cyclic molecules in adjacent crosslinks in one or more pseudopolyrotaxane and / or polyrotaxane molecules. In some other embodiments, crosslinking of cyclic molecules in the nano- or microstructure comprises parallel crosslinking of cyclic molecules in adjacent pseudopolyrotaxane and / or polyrotaxane molecules. In some preferred embodiments, crosslinking of cyclic molecules in the nano- or microstructure comprises both serial crosslinking of adjacent cyclic molecules in adjacent crosslinks in one or more pseudopolyrotaxane and / or polyrotaxane molecules and parallel crosslinking of cyclic molecules in adjacent pseudopolyrotaxane and / or polyrotaxane molecules. By crosslinking cyclic molecules in both of the above ways, the structure of cyclic molecules in the nano- or microstructure becomes stronger.

[0045] The nano- or microstructure may be formed solely from a plurality of pseudo-polyrotaxane and / or polyrotaxane molecules, or may have a columnar portion composed solely of a plurality of cyclic molecules, with no chain molecules present among the cyclic molecules. As will be described later, a nano- or microstructure having a columnar portion composed solely of a plurality of cyclic molecules can be prepared by removing the chain molecules from some or all of the pseudo-polyrotaxane and / or polyrotaxane molecules of a nano- or microstructure in which cyclic molecules are crosslinked.

[0046] In some preferred embodiments, a plurality of cyclic molecules arranged in series in a nano- or microstructure form columns, and of the total number of columns in the nano- or microstructure, the number of columns that do not include chain molecules is more than 10%, more preferably 20% or more, more preferably 30% or more, more preferably 40% or more, and more preferably 50% or more. In certain preferred embodiments, a plurality of cyclic molecules arranged in series in a nano- or microstructure form columns, and of the total number of columns in the nano- or microstructure, the number of columns that do not include chain molecules is 100%. Such nano- or microstructures can further enhance the target molecule-supporting function and the surface adhesion of target molecules.

[0047] In some preferred embodiments, of the total number of columns in the nano- or microstructure, the number of columns that encapsulate chain molecules is less than 90%, more preferably 80% or less, more preferably 70% or less, more preferably 60% or less, and more preferably 50% or less.

[0048] In some embodiments, each of the chain molecules in the multiple pseudopolyrotaxanes and / or polyrotaxanes of the nano- or microstructure has a non-ionizing group at or near both ends that does not ionize in water or an aqueous solution.

[0049] The vicinity of the chain molecule generally refers to a range of 1 to 10 monomer units, more preferably 1 to 5 monomer units, from the end of the chain molecule, excluding the end of the chain molecule.

[0050] As used herein, the term "non-ionizable group" refers to a group that does not ionize in water or an aqueous solution.

[0051] The non-ionizable group is not particularly limited as long as it satisfies the above definition, and examples thereof include an isopropyl group, a sec-butyl group, a tert-butyl group, a neopentyl group, an isopentyl group, a sec-pentyl group, a 3-pentyl group, a tert-pentyl group, a cyclopentyl group, a pentene group, a hexyl group, a hexene group, a heptyl group, a heptene group, an octyl group, an octene group, a nonyl group, a nonene group, a decyl group, a decene group, an undecyl group, an undecene group, a dodecene group, a tridecyl group, a tridecene group, a tetradecyl group, a tetradecene group, a pentadecyl group, a pentadecene group, a hexadecyl group, a hexadecene group, a heptadecyl group, a heptadecene group, an octadecene group, an octadecene group, a nonadecyl group, a nonadecene group, an eicosyl group, an ei ... Preferably, the alkyl group is at least one selected from the group consisting of cosene, henicosyl, henicosene, tetracosyl, tetracosene, triacontyl, triacontene, and their isomers, 4-isopropylbenzenesulfonyl, 1-octanesulfonyl, 4-biphenylsulfonyl, 4-tert-butylbenzenesulfonyl, 2-mesitylenesulfonyl, methanesulfonyl, 2-nitrobenzenesulfonyl, 4-nitrobenzenesulfonyl, pentafluorobenzenesulfonyl, 2,4,6-triisopropylbenzenesulfonyl, p-toluenesulfonyl, unionized hydroxyl, heptafluorobutyroyl, pivaloyl, perfluorobenzoyl, unionized amino (—NH), unionized carboxylic acid (—COOH), and isovaleryl. The non-ionizable group is preferably at least one selected from the group consisting of a non-ionized hydroxyl group, a heptafluorobutyroyl group, a perfluorobenzoyl group, and an isovaleryl group, and more preferably at least one selected from the group consisting of a perfluorobenzoyl group and an isovaleryl group.

[0052] As described above, the term "non-ionized" in "non-ionized hydroxyl group," "non-ionized amino group," and "non-ionized carboxylic acid group" means that the group is not ionized in water or an aqueous solution.

[0053] When each chain molecule has a non-ionizable group at or near both ends, one of the non-ionizable groups may be the same as or different from the other non-ionizable group. The non-ionizable group may be directly bonded to a block of the chain molecule or indirectly bonded via a spacer.

[0054] A nano- or microstructure in which each of the chain molecules in the multiple pseudo-polyrotaxanes and / or polyrotaxanes of the nano- or microstructure has non-ionizable groups that do not ionize in water or an aqueous solution at or near both ends is advantageous in that adhesion or aggregation between nano- or microstructures is suppressed.

[0055] In some preferred embodiments, each of the chain molecules in the multiple pseudopolyrotaxanes and / or polyrotaxanes of the nano- or microstructure has an ionizable group at or near both ends that ionizes under the conditions for fabricating the nano- or microstructure.

[0056] The vicinity of the chain molecule generally refers to a range of 1 to 10 monomer units, more preferably 1 to 5 monomer units, from the end of the chain molecule, excluding the end of the chain molecule.

[0057] The ionizable group is not particularly limited, but examples thereof include a carboxyl group, an amino group, a sulfo group, a phosphate group, a trimethylamino chloride group, a triethylamino chloride group, a dimethylamino group, a diethylamino group, a methylamino group, an ethylamino group, a pyrrolidine group, a pyrrole group, an ethyleneimine group, a piperidine group, a pyridine group, a pyrylium ion group, a thiopyrylium ion group, a hexamethyleneimine group, an azatropyrylene group, an imidazole group, a pyrazole group, an oxazole group, a thiazole group, an imidazoline group, a morpholine group, a thiazine group, a triazole group, a tetrazole group, a pyrimidine ... It is preferably at least one selected from the group consisting of ridazine group, pyrimidine group, pyrazine group, indole group, benzimidazole group, purine group, benzotriazole group, quinoline group, quinazoline group, quinoxaline group, pteridine group, carbazole group, porphyrin group, chlorin group, choline group, adenine group, guanine group, cytosine group, thymine group, uracil group, dissociated thiol group, dissociated hydroxyl group, azide group, pyridine group, carbamic acids, guanidines, sulfenic acids, ureas, thioureas, peracids, analogs thereof, and derivatives thereof.

[0058] When each chain molecule has ionizable groups at or near both ends, one ionizable group may be the same as or different from the other ionizable group. The ionizable group may be directly bonded to a block of the chain molecule or indirectly bonded via a spacer.

[0059] A nano- or microstructure in which each of the chain molecules in the multiple pseudo-polyrotaxanes and / or polyrotaxanes of the nano- or microstructure has an ionizable group that ionizes in water or an aqueous solution at or near both ends is advantageous in that adhesion or aggregation between nano- or microstructures is suppressed.

[0060] The nano- or microstructure according to an embodiment of the present invention comprises a plurality of pseudopolyrotaxanes and / or polyrotaxanes, but may also comprise components other than the above-described "pseudopolyrotaxanes and / or polyrotaxanes" as long as the nano- or microstructure configuration can be maintained.

[0061] Such components include, but are not limited to, a first substance that can be included in the opening of the above-mentioned cyclic molecule (also referred to as the first cyclic molecule) that constitutes the pseudopolyrotaxane and / or polyrotaxane; a second cyclic molecule that may be the same as or different from the first cyclic molecule; a second substance that can be included in the opening of the second cyclic molecule; a third substance that is different from the second substance and cannot be included in the first and second cyclic molecules; and pseudopolyrotaxanes and / or polyrotaxanes other than the "specific" pseudopolyrotaxanes and / or polyrotaxanes of the present invention.

[0062] Examples of the second cyclic molecule include, but are not limited to, those exemplified as the first cyclic molecule.

[0063] The first and second substances include, but are not limited to, drugs, fluorescent substances, chromogenic enzymes, and the like.

[0064] Such drugs include, but are not limited to, any drug including donepezil, 5-fluorouracil, hydrocortisone, betamethasone, menadione, or pharmaceutically acceptable salts thereof.

[0065] Examples of the fluorescent substance include, but are not limited to, rhodamine, Nile red, poly-L-lysine-fluorescein isothiocyanate (FITC), coumarin, Cy2, Cy3, Cy5, and the like.

[0066] Examples of the color-developing enzyme include, but are not limited to, horseradish peroxidase (HRP), alkaline phosphatase, β-galactosidase, glucose oxidase, luciferase, etc. The second substance may be the same as or different from the first substance.

[0067] The third substance can be selected depending on the application field of the isolated nano- or microstructure of the present invention, and examples include, but are not limited to, polymeric materials that do not form inclusion complexes with cyclic molecules, such as polystyrene, polyvinylpyridine, polypyridine, polyphenylene, polyacrylamide, polyacrylic acid, polymethacrylic acid, polyvinyl alcohol, polyamide, polyester, polyimide, polybenzoxazole, polyvinyl chloride, polypropylene, polysilane, and polysiloxanes; biopolymers and biomolecules such as DNA, proteins, and polypeptides; inorganic nanomaterials such as silica nanoparticles, titanium oxide nanoparticles, and silicon nanoparticles; carbon materials such as fullerenes, carbon nanotubes, graphene, graphite, and carbon quantum dots; and metal nanomaterials such as gold nanoparticles, perovskite quantum dots, CdSeS / ZnS quantum dots, and iron oxide nanoparticles.

[0068] The first substance can be contained in an opening defined by one first circular molecule, or can be contained in a space defined by multiple first circular molecules arranged in series (also shown).

[0069] The second substance can be contained in an opening defined by one second circular molecule, or in a space defined by multiple second circular molecules arranged in series (also shown).

[0070] The third substance is bound to the chain molecule, bound to the first or second cyclic molecule, or held in the space between a plurality of pseudopolyrotaxanes and / or polyrotaxanes (i.e., between a plurality of columns, particularly two, three, or four columns, which are columnar structures made of pseudopolyrotaxanes and / or polyrotaxanes). When the third substance is bound to the chain molecule, it is preferably bound to both ends or one end of the chain molecule or near there, but it may also be bound to another site on the chain molecule.

[0071] The size of the space between the multiple pseudo-polyrotaxanes and / or polyrotaxanes, the size of the opening defined by one first cyclic molecule, and the size of the space defined by multiple first cyclic molecules arranged in series can be appropriately changed by changing the length of the chain molecule, the hydrophilicity and hydrophobicity of the chain molecule, the type of first cyclic molecule, etc., and therefore the size of the opening and / or the size of the space can be appropriately changed depending on the size of the substance to be accommodated in the opening or space defined by the cyclic molecules.

[0072] Furthermore, the nano- or microstructures according to the embodiments of the present invention can be constructed from molecules that are highly biosafe and biocompatible, such as cyclodextrin and polyethylene glycol, and are therefore suitable for use in vivo.

[0073] The nano- or microstructures of the embodiments of the present invention can be used, for example, as materials for drug delivery (e.g., carriers for drug delivery), carriers for carrying food ingredients (excluding pharmaceuticals), bioimaging, surface modifiers, adhesives, adsorbents for target substances, agents for preventing adhesion at wound sites, hair care materials, coating materials, oral care materials such as mouthwash, bases for supplements, aggregation control materials for cells and algae, oxygen barrier materials, moisturizers, UV protection materials, odor prevention materials, etc., but are not limited to these.

[0074] Embodiments of the present invention also provide materials having the above-described nano- or microstructures. Such materials depend on the application field of the isolated nano- or microstructures of the present invention, and include, but are not limited to, structural materials, artificial biological replacement materials, packaging materials, rubber materials, hair care materials, coating materials, paints, oral care materials such as mouthwash, adhesives, supplement bases, high-performance beverages, aggregation control materials, oxygen barrier materials, moisturizers, UV protection materials, and odor control materials.

[0075] According to an embodiment of the present invention, foods, pharmaceuticals, and cosmetics containing the above-mentioned nano- or microstructures are provided. Food ingredients in foods, drugs in pharmaceuticals, and ingredients in cosmetics can be supported or encapsulated by nano- or microstructures. In this specification, "food" is a concept that broadly encompasses anything that can be taken orally, including beverages. Foods include general foods including health foods, as well as enteral nutritional foods, foods for special dietary uses, foods with health claims, and foods with nutrient functions. Health foods include foods offered under names such as nutritional supplements, health supplements, and supplements. "Food," "pharmaceuticals," and "cosmetics" can also be referred to as "food compositions," "pharmaceutical compositions," and "cosmetic compositions," respectively.

[0076] According to an embodiment of the present invention, there is provided a method for manufacturing a nano- or microstructure, the method comprising: crosslinking a nano- or microstructure comprising a plurality of cyclic molecules each having an opening and a plurality of chain molecules, each of the chain molecules forming a plurality of pseudo-polyrotaxanes and / or polyrotaxanes in which some of the cyclic molecules are skewered and encapsulated, to obtain a nano- or microstructure in which all or some of the adjacent cyclic molecules in the nano- or microstructure are crosslinked to each other.

[0077] 1(A)-(E) are referenced to facilitate understanding of the present invention, but are not intended to limit the scope of the present invention. In FIG. 1(A), a cyclic molecule 10 and a linear polymer 20 serving as a linear molecule are prepared and then mixed in water or an aqueous solution. Examples of aqueous solutions include, but are not limited to, an alcoholic aqueous solution, an acidic aqueous solution, an alkaline aqueous solution, a buffer solution, a culture medium, and plasma. For example, the cyclic molecule 10 may be cyclodextrin, and the linear polymer 20 is a linear polymer consisting of three blocks 20a, 20b, and 20c, where blocks 20a and 20c are polyethylene glycol and 20b is polypropylene glycol. By mixing the cyclic molecules 10 and the linear polymers 20, as shown in Figure 1(B), the linear polymers 20 skewer through multiple cyclic molecules 10, and pseudo-polyrotaxanes 30 are generated in which blocks 20b of the linear polymers 20 are encapsulated by multiple cyclic molecules 10.Multiple of these pseudo-polyrotaxanes aggregate to obtain nanosheets 40 as nano- or microstructures comprising multiple pseudo-polyrotaxanes 30, as shown in Figure 1(C).

[0078] Optionally, the nanosheet manufacturing method of the present invention may include a step of pre-introducing the above-mentioned non-ionizable groups or ionizable groups to both ends or their vicinity of the chain molecules before mixing with the cyclic molecules.

[0079] Furthermore, the method for producing a nanosheet according to an embodiment of the present invention may include a step of modifying the pseudopolyrotaxane before obtaining the nanosheet, or the pseudopolyrotaxane that is part of the obtained nanosheet.

[0080] The modification step may be a step of introducing a substituent to the end of the chain molecule. The substituent may be a blocking group that blocks the cyclic molecule from detaching, a group that acts as a non-ionizing group and / or an ionizing group, or a group that has other functions, as long as an isolated nanosheet is obtained. The first substituent may have any combination of these functions, or may have all of these functions.

[0081] For example, groups having a blocking action and a non-ionizing group action include an adamantane group, a neopentyl group, an isopentyl group, a sec-pentyl group, a 3-pentyl group, a tert-pentyl group, a cyclopentyl group, a pentene group, a hexyl group, a hexene group, a heptyl group, a heptene group, an octyl group, an octene group, a nonyl group, a nonene group, a decyl group, a decene group, an undecyl group, an undecene group, a dodecyl group, a dodecene group, a tridecyl ... Examples of such alkyl groups include, but are not limited to, decene, tetradecyl, tetradecene, pentadecyl, pentadecene, hexadecyl, hexadecene, heptadecyl, heptadecene, octadecyl, octadecene, nonadecyl, nonadecene, eicosyl, eicosene, henicosyl, henicosene, tetracosyl, tetracosene, triacontyl, triacontene, and isomers thereof.

[0082] As a group having an ionizable group function, groups derived from folic acid, biotin, fluorescein, oligopeptides such as RGD and GRGDS, and monoclonal antibodies such as rituximab, bevacizumab, tocilizumab and infliximab may be introduced. For example, when introducing a group derived from folic acid, the resulting isolated sheet and folic acid can be reacted in the presence of a condensing agent such as DMT / MM (4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride), DCC (N,N'-dicyclohexylcarbodiimide), EDC (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide), BOP (benzotriazol-1-yloxy-trisdimethylaminophosphonium salt), PyBOP ((benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate), or HATU (O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate).

[0083] The above-described method for producing a nanosheet comprising a plurality of cyclic molecules each having an opening and a plurality of chain molecules, each of which is skewered and enclosed by a corresponding part of the cyclic molecules to form a plurality of pseudopolyrotaxanes and / or polyrotaxanes, is known, as described in, for example, WO2020 / 013215 and WO2020 / 175679.

[0084] In the nanosheet manufacturing method of the embodiment of the present invention, as shown in Figure 1(D), the nanosheet 40 is further crosslinked using a crosslinking agent 50 or the like to obtain a nanosheet 42 in which adjacent cyclic molecules among the multiple cyclic molecules in each of some or all of the multiple pseudopolyrotaxanes and / or polyrotaxanes are crosslinked to each other.

[0085] Cross-linking of adjacent cyclic molecules is known, see, for example, E. Renard et al., European Polymer Journal, Volume 33, Issue 1, Pages 49-57, 1997; Harada et al., Nature Volume 364, Pages 516-518, 1993; Furukawa et al., Angewandte Chemie Volume 51, Issue 42, Pages 10566-10569, 2012; Zhu et al., Langmuir 2013, 29, 20, 5939-5943, 2013).

[0086] In a method of crosslinking adjacent cyclic molecules via a crosslinking agent having a reactive functional group capable of reacting with the functional group of the cyclic molecule, a combination of a functional group of the cyclic molecule and a crosslinking agent having a reactive functional group capable of reacting with the functional group of the cyclic molecule is known. Examples of functional groups of the cyclic molecule include a hydroxyl group, a carboxyl group, and an amino group. Examples of reactive functional groups of the crosslinking agent include an isocyanate group, a thioisocyanate group, an epoxy group, and a dicarboxylic acid anhydride group. A crosslinking agent having two or more reactive functional groups is advantageous in that it can crosslink two molecules of cyclic molecules via one molecule of the crosslinking agent. Examples of such compounds having two or more reactive functional groups include, but are not limited to, oxirane compounds such as epichlorohydrin and epibromohydrin, diisocyanates such as hexamethylene diisocyanate, oxetane compounds such as 3-(chloromethyl)-3-methyloxetane, tricarboxylic acid chlorides such as 1,3,5-benzenetricarbonyl trichloride, dicarboxylic acid chlorides such as adipic acid dichloride, glutaric acid dichloride, 4,4'-oxydibenzoyl chloride, oxalic acid dichloride, succinic acid dichloride, suberic acid dichloride, terephthaloyl dichloride, diglycolyl chloride, 2,5-furandicarbonyl dichloride, and sebacic acid dichloride.

[0087] For example, E. Renard et al., European Polymer Journal, Volume 33, Issue 1, Pages 49-57, 1997, describes the cross-linking of hydroxyl groups of β-cyclodextrin using epichlorohydrin as a cross-linking agent, as shown in Scheme 1 below.

[0088] [ka]

[0089] The crosslinking reaction may be carried out in aqueous or organic solvents, including, but not limited to, water, acetone, ethanol, ethyl methyl ketone, glycerin, ethyl acetate, methyl acetate, diethyl ether, cyclohexane, dichloromethane, 1,1,2-tetrafluoroethane, 1,1,2-trichloroethene, 1-butanol, 2-butanol, butane, 1-propanol, 2-propanol, propane, propylene glycol, hexane, methanol, and 15-crown-5 ether. The progress of the crosslinking reaction can be confirmed by analyzing the crystal structure using grazing incidence wide-angle X-ray scattering.

[0090] By connecting multiple pseudopolyrotaxanes and / or cyclic molecules in polyrotaxanes in series or in parallel, the structure in the nanosheet becomes stronger.

[0091] The nanosheet manufacturing method of the present invention may further include a step of removing some or all of the multiple chain polymers 20 that are skewered and enclosed in some of the multiple cyclic molecules 10, as shown in Figure 1(E), after obtaining a nanosheet 42 in which the cyclic molecules are crosslinked to each other as shown in Figure 1(D).

[0092] Methods for removing the linear polymer 20 from the cyclic molecules 10 are known. For example, see Langmuir 2013, 29, 5939-5943 (https: / / pubs.acs.org / doi / 10.1021 / la400478d). This document describes dispersing composite particles in which polyethylene glycol (PEG) is encapsulated in crosslinked α-CD in chloroform, and then centrifuging the crosslinked CD particles (low solubility) and PEG (high solubility) in chloroform to obtain free crosslinked CD particles. The linear polymer 20 can be removed from the cyclic molecules 10 by dispersing the nanosheets in water or organic solvents such as chloroform, ethanol, acetone, and hexane, centrifuging the dispersion, removing the supernatant, and then dispersing the nanosheets in a polar solvent, repeating this washing process one or more times.

[0093] In the nanosheet of the embodiment of the present invention, the cyclic molecules in the nanosheet 42 are cross-linked to each other, so that even if a step of removing the chain polymer 20 from the cyclic molecule 10 is performed, the structure of the cross-linked cyclic molecule is maintained.

[0094] In the nanosheet 44 obtained by removing the chain polymer 20 from the cyclic molecule 10, the amount of the chain polymer 20 in the nanosheet 44 is reduced or completely removed. This increases the effective space available for supporting, accommodating, and adsorbing the target molecule in the opening formed by one cyclic molecule 10 and the space within the column partitioned by multiple cyclic molecules 10 in the nanosheet 44. This further enhances the target molecule supporting function of the nanosheet 44 configured in this way, and the surface adhesion of the target molecule (adsorbed substance) derived from the nanosheet structure.

[0095] Optionally, the manufacturing method of the present embodiment may include a step for introducing one or more of the second cyclic molecule, the first substance, the second substance, and the third substance described above into the nanosheets 42, 44.

[0096] In order to facilitate understanding of the invention, the nano- or microstructure has been described above as being embodied as a nanosheet, but the nano- or microstructure of the present invention may be a nano- or microstructure other than a nanosheet.

[0097] 2 shows an example of such a nano- or microstructure. A nano- or microstructure 40' according to one embodiment of the present invention has a plurality of pseudopolyrotaxanes and / or polyrotaxanes 30, each of which has a chain polymer 20 that skewer-likely encapsulates the opening of a cyclic molecule 10, and at least some of the pseudopolyrotaxanes and / or polyrotaxanes 30 are arranged in series. Another portion of the pseudopolyrotaxanes and / or polyrotaxanes 30 are arranged in parallel. A plurality of pseudopolyrotaxanes and / or polyrotaxanes 30 are arranged in the thickness direction of the sheet of the nano- or microstructure 40' and in each of two directions perpendicular to the thickness direction of the sheet. Specifically, in this figure, two pseudopolyrotaxanes and / or polyrotaxanes 30 are arranged in series, and 17×10 pairs of pseudopolyrotaxanes and / or polyrotaxanes 30 are arranged in parallel.

[0098] The phrase "plurality of pseudo-polyrotaxanes and / or polyrotaxanes arranged in series" means that plural pseudo-polyrotaxanes and / or polyrotaxanes are stacked and arranged in the axial direction of their cyclic molecules. It is preferable that the axial directions of one pseudo-polyrotaxane and / or polyrotaxane arranged in series with another pseudo-polyrotaxane and / or polyrotaxane are approximately the same, and that the cyclic molecules are arranged in a substantially straight line. However, as long as the cyclic molecules are stacked and arranged in the axial direction of the cyclic molecules, the positions of the individual cyclic molecules may be slightly shifted in the direction perpendicular to the axial direction.

[0099] The phrase "plural pseudo-polyrotaxanes and / or polyrotaxanes are arranged in parallel" means that the pseudo-polyrotaxanes and / or polyrotaxanes are arranged in approximately parallel to each other. It is preferable that the axial directions of the pseudo-polyrotaxanes and / or polyrotaxanes arranged in parallel to each other and the axial directions of the other pseudo-polyrotaxanes and / or polyrotaxanes are approximately parallel to each other.

[0100] The size of the nano- or microstructure 40' is not particularly limited, but the dimensions of the crystals of the nano- or microstructure 40' along the a-axis, b-axis, and c-axis are typically on the order of nanometers (1 nm or more and less than 1000 nm) or micrometers (1 μm or more and less than 1000 μm). The pharmacokinetic behavior in the body varies depending on the particle size of the nano- or microstructure 40'. For example, nano- or microstructures 40' of ≥2 mm are taken up by liver cells, nano- or microstructures ≥300-400 nm are captured and excreted by macrophages, nano- or microstructures ≥200 nm are processed in the spleen, and nano- or microstructures 40' of ≥100 nm pass through vascular endothelial cells. Therefore, the size of the nano- or microstructure 40' can be selected and designed according to the purpose. Note that a structure 1 having a dimension of 1 μm or more along at least one of the a-axis, b-axis, and c-axis may be referred to as a "microstructure" in this specification.

[0101] The nano- or microstructure may be rod-shaped, with the length in the c-axis direction greater than the lengths in the a- and b-axes; cube-shaped, with the length in the c-axis direction approximately equal to the lengths in the a- and b-axes; or sheet-shaped, with the length in the c-axis direction less than the lengths in the a- and b-axes. Furthermore, when the structure is sheet-shaped, the shape of the sheet when viewed from above may be approximately square, approximately rectangular, rhombic, or polygonal (with 3, 4, 5, 6, or more sides). Furthermore, the nano- or microstructure may be tent-shaped, i.e., hollow pyramidal, polyhedral, columnar (prism-shaped or cylindrical; including solid or hollow), or spherical (including solid or hollow).

[0102] When the nano- or microstructure is rod-shaped, the thickness (length in the c-axis direction) is preferably 100 nm or more, more preferably 100 nm to 1000 μm, and even more preferably 200 nm to 100 μm, and the lengths in the a-axis and b-axis directions are each preferably 50 nm or more, more preferably 50 nm to 100 μm, and even more preferably 100 nm to 10 μm.

[0103] When the nano- or microstructure is cubic, the thickness (length in the c-axis direction) is preferably 50 nm or more, more preferably 50 nm to 1000 μm, and even more preferably 100 nm to 100 μm.

[0104] When the nano- or microstructure is sheet-shaped, the thickness (length in the c-axis direction) is preferably 50 nm or more, more preferably 50 nm to 100 μm, and even more preferably 100 nm to 10 μm, and the lengths in the a-axis and b-axis directions are each preferably 100 nm or more, more preferably 100 nm to 1000 μm, and even more preferably 200 nm to 100 μm.

[0105] The structure of the nano- or microstructure can be appropriately controlled by changing the molecular weight, hydrophilicity and hydrophobicity, topology, and polymer block of the chain molecule.

[0106] The cyclic molecules 10 and the chain polymers 20 are as described in relation to the method for producing the nanosheet shown in FIG.

[0107] Examples of the cyclic molecule 10 include, but are not limited to, cyclodextrins (e.g., α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin), crown ethers, pillararenes, calixarenes, cyclophanes, cucurbiturils, and derivatives thereof. Examples of derivatives include, but are not limited to, methylated α-cyclodextrin, methylated β-cyclodextrin, methylated γ-cyclodextrin, hydroxypropylated α-cyclodextrin, hydroxypropylated β-cyclodextrin, hydroxypropylated γ-cyclodextrin, etc.

[0108] The weight average molecular weight of the chain polymer 20 is preferably 2,000 to 200,000, more preferably 4,000 to 100,000, and even more preferably 6,000 to 50,000.

[0109] In one preferred embodiment, the chain polymer 20 is water-soluble, and examples thereof include at least one selected from the group consisting of polyethylene oxide (polyethylene glycol), polypropylene oxide (polypropylene glycol), polyvinyl alcohol, polyethyleneimine, polyacrylic acid, polymethacrylic acid, polyacrylamide, cellulose derivatives such as hydroxypropyl cellulose, and polyvinylpyrrolidone, and more preferably at least one selected from the group consisting of polyethylene glycol and polypropylene glycol.

[0110] The weight average molecular weight of the water-soluble chain polymer 20 is preferably 200 to 200,000, more preferably 200 to 50,000, and even more preferably 200 to 20,000.

[0111] The linear polymer 20 may have a segment formed by the polymerization of one type of monomer or may be a polymer consisting only of such a segment, a copolymer formed by the polymerization of two types of monomers or may be a polymer consisting only of such a copolymer segment, or a terpolymer formed by the polymerization of three types of monomers or may be a polymer consisting only of such a terpolymer segment. Examples of such segments include those mentioned above as the backbone forming the repeating structure. In particular, examples of such segments include, but are not limited to, at least one selected from the group consisting of polyethylene glycol, polyisoprene, polyisobutylene, polybutadiene, polypropylene glycol, polytetrahydrofuran, polydimethylsiloxane, polyethylene, polypropylene, polyvinyl alcohol, and polyvinyl methyl ether.

[0112] The chain polymer 20 can be a block copolymer having two blocks. Alternatively, the chain polymer 20 can be a block copolymer having three blocks. When both ends of the chain polymer 20 are accommodated in a column consisting of a plurality of cyclic molecules 10, adjacent cyclic molecules 10 of the pseudopolyrotaxane and / or polyrotaxane can be arranged in series by non-covalent interactions. In order for both ends of the chain polymer 20 to be accommodated in a column consisting of a plurality of cyclic molecules 10, it is preferable that no hydrophilic PEO blocks are arranged at both ends of the chain polymer 20, or that even if a hydrophilic PEO block is arranged, its length is 0.20 nm or less.

[0113] Preferred examples of the linear polymer 20 include, but are not limited to, a single-block polymer made of polyethylene oxide (PEO), a diblock copolymer made of a block of polyethylene oxide (PEO) and a block of polypropylene oxide (PPO), a block of polypropylene oxide (PPO), and a block of polyethylene oxide (PEO) in that order, etc. A triblock polymer made of PEO-PPO-PEO is preferred because PPO is more hydrophobic than PEO and cyclic molecules are more selectively aligned and included in the PPO.

[0114] When the chain polymer 20 is a block copolymer, the chain length of the site where the cyclic molecule 10 includes the chain polymer 20 is preferably longer than the thickness of the cyclic molecule 10 .

[0115] The chain polymer 20 may have an ionizable group that ionizes in water or an aqueous solution. In one preferred embodiment, the chain polymer 20 has an ionizable group at or near at least one end. In another preferred embodiment, the chain polymer 20 has an ionizable group at at least one end. In another preferred embodiment, the chain polymer 20 has ionizable groups at both ends.

[0116] Instead of the ionizable group, the chain polymer 20 may have a non-ionizable group. Conventionally known methods can be used to introduce the ionizable group or non-ionizable group into the chain polymer. The ionizable group and non-ionizable group are as described in the nanosheet embodiment. For example, a nano- or microstructure in which the cyclic molecule 10 is γ-cyclodextrin (hereinafter, γ-CD) and the chain polymer 20 is polyethylene oxide (PEO) will be used for explanation.

[0117] First, regarding the effect of the molecular weight of the chain polymer, the dependence of the crystal growth of nano- or microstructures on the length of the PEO axis is summarized in Figure 3(A)-(C). When the chain polymer 20 is PEO, the cyclic molecule 10 forms a double-chain complex with the chain polymer 20.

[0118] As shown in Figure 3(A), when the molecular weight of the linear polymer 20 is small and the axis is short, a rod-shaped nano- or microstructure is formed in which pseudopolyrotaxanes and / or polyrotaxanes 30 are stacked in the c-axis direction, i.e., parallel to the main axis of the linear polymer 20. This indicates that the crystal growth of the cyclic molecules 10 in the c-axis direction is faster than that in the a-axis and b-axis directions, which are perpendicular to the c-axis. In contrast, as the axis of the linear polymer 20 increases, the lateral length of the nano- or microstructure in the c-axis direction becomes shorter. This indicates that for longer linear polymers 20, the crystal growth of the cyclic molecules 10 along the a-axis and b-axis is faster than that along the c-axis. When the length of the pseudopolyrotaxane and / or polyrotaxane 30 is short, the lateral interaction is weaker than that of longer pseudopolyrotaxanes and / or polyrotaxanes 30, and the pseudopolyrotaxane and / or polyrotaxane 30 is thought to extend in the c-axis direction.

[0119] In the example shown in Figure 3(B), when the length of the chain polymer 20 is made longer than that of Figure 3(A), the lateral interaction becomes greater than that of Figure 3(A), and a cubic nano- or microstructure is formed in which the length in the c-axis direction is equal to the lengths in the a-axis and b-axis directions.

[0120] In the example shown in FIG. 3(C), when the length of the chain polymer 20 is made even longer than that in FIG. 3(B), a sheet-like nano- or microstructure is formed that is longer in the a-axis and b-axis directions than in the c-axis direction.

[0121] When the length of the chain polymer 20 is increased beyond that shown in FIG. 3(C), the chain polymer 20 begins to bend, as shown in FIG. 3(D), and the bent portions of the chain polymer 20 hinder crystal growth along the c-axis of the cyclic molecule 10, resulting in the formation of a sheet-like nano- or microstructure. The portion of the chain polymer 20 including the bent portion protrudes from the cyclic molecule 10. In this way, by changing the length or molecular weight of the chain polymer 20, the behavior of the crystals in the nano- or microstructure formed by the cyclic molecule 10 can be controlled.

[0122] Next, we will explain the effect of the hydrophilicity and hydrophobicity of the chain polymer 20. When the cyclic molecule 10 is γ-CD and the chain polymer 20 is PEO, nano- or microstructures of various shapes are formed as the molecular weight changes, as described above. In contrast, when the chain polymer 20 is hydrophobic polypropylene oxide (PPO) instead of hydrophilic PEO, as the chain polymer 20 becomes longer, the shape changes to a rod shape in which the length in the c-axis direction is greater than the length in the a- and b-axes, a cube shape in which the length in the c-axis direction is approximately equal to the length in the a- and b-axes, a sheet shape in which the length in the c-axis direction is smaller than the length in the a- and b-axes, and finally a random (disordered) shape. Thus, the hydrophilicity and hydrophobicity of the chain polymer 20 can also affect the crystalline behavior of the nano- or microstructure.

[0123] Although not wishing to be bound by theory, the above phenomenon is thought to be due to the fact that when the chain polymer 20 is hydrophilic, hydration occurs on the surface of the nano- or microstructure, stabilizing the structure, whereas when the chain polymer 20 is hydrophobic, hydrophobic aggregation competes with the crystallization of γ-CD, resulting in disorder.

[0124] Next, we will explain the effect of the topology of the chain polymer 20. When the chain polymer 20 is a single-chain PEO, structures of various shapes are formed as the molecular weight changes, as described above. In contrast, when PEO with branch points P (Figure 4(A)) is used as the chain polymer 20', the branch points P suppress crystal growth, as shown in Figure 4(B), and a sheet-like nano- or microstructure 40' of uniform thickness is formed. However, as shown in Figure 4(C), the chain polymer 20' acts as a bridge, connecting the sheets together. In this way, the topology of the chain polymer 20 can affect the behavior of the crystals in the nano- or microstructure.

[0125] Next, we will explain the effect of changing the polymer block configuration. For example, as shown in Figures 5(A)-(C), a block triblock polymer is used as the linear polymer 20. The central block is PPO with a molecular weight of 3.3k ("k" stands for kilo, and the same applies below), and the flanking blocks are PEO with molecular weights of 0.2k, 1.1k, and 6.5k, respectively. In this case, a block structure 40" as a nano- or microstructure shown in Figures 5(D)-(F) is formed. In either case, the strength of the interaction between γ-CD and PPO is stronger than that between γ-CD and PEO, and γ-CD is localized in the axial center of the linear polymer 20. By utilizing this, a hydrophobic PPO block can be placed in the center of the linear polymer and hydrophilic PEO blocks can be placed at both ends. The PEO blocks at both ends of the linear polymer 20 can protrude from the columns composed of multiple γ-CDs, thereby producing a monolayer sheet with a uniform thickness, i.e., a sheet in which one pseudopolyrotaxane and / or polyrotaxane is arranged in the thickness direction.

[0126] The nano- or microstructure 40′ may further include components other than the pseudopolyrotaxane and / or polyrotaxane 30, i.e., an additional substance 60 (shown in FIG. 6(A)) other than the cyclic molecule 10 and the chain polymer 30 that encapsulates the opening of the cyclic molecule 10 in a skewered manner.

[0127] The substance 30 may be bonded to a cyclic molecule 10, a linear polymer 20, held in a space 4 (shown in FIG. 2 ) between multiple pseudopolyrotaxanes and / or polyrotaxanes 30 (i.e., between multiple, particularly two, three, or four, columns, which are columnar structures made of pseudopolyrotaxanes and / or polyrotaxanes), accommodated in an opening 14 defined by a single cyclic molecule 10, or accommodated in a space 6 defined by multiple cyclic molecules 10 (shown in FIG. 6(A) ). When the substance 60 is bonded to the linear polymer 20, it is preferably bonded to both ends or one end of the linear polymer 20 or in the vicinity thereof, but it may also be bonded to another site on the linear polymer 20. Furthermore, it is preferable that the linear polymer 20 is not contained in the space 6 defined by multiple cyclic molecules 10 in terms of accommodating the substance 60, but molecules other than the substance 60, such as the linear polymer 20, may be contained therein.

[0128] The size of the space 4 between the multiple pseudo-polyrotaxanes and / or polyrotaxanes 30, the size of the opening 14 partitioned by one cyclic molecule 10, and the size of the space 6 partitioned by the multiple cyclic molecules 10 can be appropriately changed by changing the type of cyclic molecule 10, the length of the chain polymer 20, the hydrophilicity and hydrophobicity of the chain polymer 20, etc., and therefore the size of the space 4, the size of the opening 14, and / or the size of the space 6 can be appropriately changed depending on the size of the substance 60 to be accommodated.

[0129] The nano- or microstructure 40' of this embodiment is thicker than a conventional single-layer nanosheet, and therefore a single structure can incorporate a large amount of a substance 60 such as a drug. Therefore, the nano- or microstructure 40' of this embodiment can function as a vehicle for the drug, enabling the sustained release of the drug for a longer period of time.

[0130] Furthermore, the nano- or microstructure 40' of this embodiment is made of molecules that are highly safe for living organisms, and is therefore suitable for use in living organisms.

[0131] Furthermore, the nano- or micro-structure 40' of this embodiment can be produced more quickly by using the short chain polymer 20 as a raw material, and energy and costs can also be reduced.

[0132] As shown in Figures 6(A)-(F), the cyclic molecules 10 and chain polymers 20 in the nano- or microstructure 40' can have various configurations as long as they maintain the structure of the nano- or microstructure 40' as an aggregate, as long as the nano- or microstructure 40' can perform the intended function.

[0133] For example, in FIG. 6(A), a plurality of (six in the figure) cyclic molecules 10 form a column, and a single chain polymer 20 is accommodated inside a space 6 formed by a series of openings 14 of the cyclic molecules 10. Although the single chain polymer 20 extends across the openings 14 of the cyclic molecules 10, both ends of the chain polymer 20 do not reach both ends of the column made up of the plurality of cyclic molecules 10, and the column is accommodated in the space 6. Note that a column made up of a plurality of cyclic molecules 10 can also be referred to as a stack made up of a plurality of cyclic molecules 10. A substance 60 may or may not be accommodated in the openings 14 of the cyclic molecules 10 or the space 6 formed by the plurality of cyclic molecules 10.

[0134] In Figure 6(B), two chain polymers 20 are accommodated inside the space 6, and the two chain polymers 20 extend across the openings 14 of the multiple cyclic molecules 10, with both ends of the chain polymer 20 reaching both ends of the column made up of the multiple cyclic molecules 10, and the total height of the multiple cyclic molecules 10 constituting one pseudopolyrotaxane and / or polyrotaxane 2 roughly corresponds to the total length of the chain polymer 20.

[0135] 6(C), both ends of the chain polymer 20 slightly protrude outward from the cyclic molecule 10. One end of the main body 22 of the chain polymer 20 is provided with a modifying group .

[0136] In FIG. 6(D), one end 24 of the chain polymer 20 is accommodated in the space 6, and the other end 26 slightly protrudes from the cyclic molecule 10.

[0137] 6(E), a single chain polymer 20 is accommodated in the space 6, and this chain polymer 20 extends into the openings 14 of the four cyclic molecules 10, but does not extend into the openings 14 of the top and bottom cyclic molecules 10. In other words, the length of the chain polymer 20 is short, being half or less of the length of the space 6 (i.e., the total height of the multiple cyclic molecules 10).

[0138] 6(F) shows only a column made up of a plurality of cyclic molecules 10, without any chain polymer 20. In this embodiment, a substance 60 is contained in the space 6 formed by the plurality of cyclic molecules 10.

[0139] In one preferred embodiment, each of the columns of the multiple cyclic molecules 10 in the nano- or microstructure 40′ is provided with a chain polymer 20. In another preferred embodiment, among the columns of the multiple cyclic molecules 10 in the nano- or microstructure 40′, some of the columns are provided with a chain polymer 20, and the remaining columns are not provided with a chain polymer 20.

[0140] As described above, the size of space 4, the size of opening 14, and / or the size of space 6 can be designed and adjusted as appropriate depending on the size of substance 60 to be contained. Furthermore, the occupancy of these spaces 4, the size of opening 14, and / or the size of space 6 in nano- or microstructure 40' can also be designed and adjusted as appropriate. Therefore, for example, if substance 60 is a drug, a desired amount of drug can be contained in space 4, opening 14, and / or space 6 of nano- or microstructure 40', and nano- or microstructure 40' can function as a drug encapsulation body or a drug release control carrier.

[0141] The amount of substance 60 in the nano- or microstructure 40' can be measured by absorbance measurement. For example, a calibration curve of substance concentration vs. absorbance at a predetermined wavelength is measured in advance for a solution of a known concentration of substance 60 dissolved in a solvent. A predetermined amount of nano- or microstructure 40' is dissolved in the same solvent, and the absorbance is measured to determine the absorbance value at the predetermined wavelength. The concentration of the substance is calculated from the obtained absorbance value and the calibration curve, and the amount of substance 60 in the nano- or microstructure 40' is calculated. In one embodiment, the amount of substance 60 in the nano- or microstructure 40' is 0.0001% by mass or more, more specifically, 0.001 to 11% by mass, but is not limited to this. When referring to a substance 60 in a nano- or microstructure 40' or a substance 60 encapsulated in a nano- or microstructure 40', the substance 60 includes a substance contained within the space 6 defined by the cyclic molecules 10, a substance 60 that is not encapsulated in a cyclic molecule 10 but exists between multiple cyclic molecules 10, and a substance 60 that is not encapsulated in a cyclic molecule 10 but is attached to the outer surface of the nano- or microstructure 40' rather than between multiple cyclic molecules 10.

[0142] Next, a method for manufacturing a nano- or micro-structure will be described.

[0143] The present embodiment provides methods I and II for manufacturing a nano- or microstructure.

[0144] <Manufacturing method I> The production method I is a) preparing a cyclic molecule 10; b) providing a linear polymer 20; and c) mixing the cyclic molecule 10 and the linear polymer 20 in water or an aqueous solution; and by this production method, it is possible to obtain a nano- or microstructure having a plurality of pseudo-polyrotaxanes in which the openings of the cyclic molecule 10 are skewered and enclosed by the linear polymer 20, and in which at least some of the plurality of pseudo-polyrotaxanes and / or polyrotaxanes are arranged in series with each other.

[0145] In step c), the pseudopolyrotaxanes and / or polyrotaxanes contained in the column, each having a chain polymer at both ends of which is made up of a plurality of cyclic molecules, interact with each other, and at least some of the pseudopolyrotaxanes and / or polyrotaxanes are arranged in series with each other.

[0146] The "cyclic molecule 10" and "chain polymer 20" are as described above. <Step a)> Step a) is a step of preparing a cyclic molecule 10.

[0147] In this step, commercially available cyclic molecules can be purchased or prepared. When preparing derivatives, they can be obtained by the method described in, for example, Reference 1: Khan, AR et al., Chem Rev 1998, 98(5), 1977-1996. <Step b)> Step b) is a step of preparing a chain polymer 20 having a chain polymer 20 .

[0148] Here, the chain polymer 20 may be commercially available or may be prepared. When preparing the "chain polymer 20", it can be obtained by the methods described in the following documents 2 to 5. Reference 2: Hillmyer, MA et al., Macromolecules 1996, 29(22) 6994-7002. Reference 3: Ding, JF et al., Eur Polym J 1991, 27(9), 901-905. Reference 4: Allegaier, J. et al., Macromolecules 2007, 40(3), 518-525. Reference 5: Malik, MI et al., Eur Po.ym J 2009, 45(3), 899-910. <Step b)> Step a) may be performed before step c). That is, steps a) and b) may be performed separately, and either may be performed first. <Process c)> Step c) is a step of mixing the cyclic molecule 10 and the linear polymer 20 in water or an aqueous solution. The water or aqueous solution is not particularly limited as long as it is a solvent in which at least one of the cyclic molecule 10 and the linear polymer 20 can be dissolved.

[0149] Specific examples of the water or aqueous solution used in step c) include pure water, an aqueous alcohol solution, an aqueous acid solution, an aqueous alkali solution, a buffer solution, a culture medium, and a serum. However, the water or aqueous solution is not limited to these.

[0150] By carrying out the above steps a) to c), the above nano- or micro-structure can be obtained.

[0151] The above-described manufacturing method may include steps other than the above steps a) to c). Examples of steps other than the above steps a) to c) include, but are not limited to, a step of preparing the above-described "chain polymer 20" before step b), a step of purifying the nano- or microstructure after step c), and a step of inclusion of a cyclic molecule with a first substance or synthesis of a pseudopolyrotaxane or polyrotaxane, which may be performed before step b). Furthermore, when the nano- or microstructure contains the above-described substance 60, the manufacturing method of this embodiment may include a step of introducing the substance 60 into the nano- or microstructure.

[0152] Furthermore, it is preferable to further include, after step c), a step of modifying a part of the pseudo-polyrotaxane of the obtained nano- or microstructure.

[0153] The modification step may be a step of introducing a first substituent into the chain polymer 20, for example, at the end of the chain polymer 20. The first substituent may be a blocking group that blocks the cyclic molecule 10 so that it does not detach, or may have other functions, as long as a nano- or microstructure is obtained. The first substituent may have any combination of these functions, or may have all of these functions.

[0154] For example, the groups having a blocking effect can be the groups described for the groups having a blocking effect and a non-ionizing effect on the nanosheets.

[0155] As other functions, for example, a group having the function of an ionizable group can be mentioned, and the groups described for the group having the function of an ionizable group of the nanosheet can be used.

[0156] The modification step may be a step of introducing a second substituent into the cyclic molecule 10, as long as a structure is obtained. <Manufacturing method II> Production Method II is a) preparing a cyclic molecule 10; b') preparing a linear polymer 20; c') mixing the cyclic molecule 10 and the linear polymer 20 in water or an aqueous solution to obtain a pseudopolyrotaxane; d) introducing substituents into both ends of at least a part of the chain polymer 20 to form the chain polymer 20; e) introducing blocking groups into both ends of the chain polymer 20 of the pseudopolyrotaxane and / or at least a portion of the chain polymer 20; f) mixing the obtained pseudopolyrotaxane and / or polyrotaxane in water or an aqueous solution; By this production method, it is possible to obtain a structure having a plurality of pseudo-polyrotaxanes in which the openings of the cyclic molecules 10 are skewered and enclosed by the chain polymers 20, and in which at least some of the plurality of pseudo-polyrotaxanes and / or polyrotaxanes are arranged in series with each other.

[0157] In step f), the pseudopolyrotaxanes and / or polyrotaxanes contained in the column, each having a chain polymer at both ends of which is made up of a plurality of cyclic molecules, interact with each other, and at least some of the pseudopolyrotaxanes and / or polyrotaxanes are arranged in series with each other.

[0158] Here, step a) is the same as the above-mentioned "step a)." Step b') can use the "chain polymer 20" described in the above-mentioned step b).

[0159] Step c') is a step of mixing the cyclic molecule 10 and the linear polymer 20 in water or an aqueous solution, similar to the above step c), thereby obtaining a pseudo-polyrotaxane. As described in step c), the water or aqueous solution is not particularly limited as long as it is a solvent that dissolves at least one of the cyclic molecule 10 and the linear polymer 20.

[0160] Specific examples of the water or aqueous solution used in step c) include pure water, an aqueous alcohol solution, an aqueous acid solution, an aqueous alkali solution, a buffer solution, a culture medium, and plasma, but are not limited to these.

[0161] Step d) is a step of introducing substituents into both ends of at least a part of the chain polymer 20 to form the chain polymer 20 .

[0162] Non-limiting examples of the introduction of the above substituents include the introduction of a carboxylic acid by an oxidation reaction using hypochlorous acid and 2,2,6,6-tetramethylpiperidine 1-oxyl, the introduction of an amino group by a coupling reaction using 1'-carbonyldiimidazole and ethylenediamine, and the introduction of a sulfo group by reacting 1,3-propane sultone with the linear polymer 20.

[0163] Non-limiting examples of the introduction of other substituents include condensation reactions such as esterification and amidation using condensing agents such as DMT / MM (4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride), DCC (N,N'-dicyclohexylcarbodiimide), EDC (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide), BOP (benzotriazol-1-yloxy-trisdimethylaminophosphonium salt), PyBOP ((benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate), and HATU (0-(7-dibenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate), but are not limited to these.

[0164] Step e) is a step of introducing a so-called blocking group, which reduces the rate of elimination of the cyclic molecule 10. This step can be performed using a conventionally known method, such as the process described in Harada et al., Nature, 1992, 356, 325-327. The blocking group can also be a conventionally known blocking group that can be used for polyrotaxanes. For example, the blocking groups described in M. Okada et al., J. Polym. Sci. A: Polym. Chem, 2000, 38, 4839-4849 can be used.

[0165] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these examples. [Example]

[0166] Synthesis Example 1: Synthesis of α,ω-bis-aminopolyethylene glycol-block-polypropylene glycol-block-polyethylene glycol A 10 mL tetrahydrofuran solution of α,ω-bis-hydroxypolyethylene glycol-block-polypropylene glycol-block-polyethylene glycol (Pluronic® F68; PEO76PPO29PEO76, Mw=8400 g / mol; 1 g, 0.119 mmol) was prepared and added dropwise to a separately prepared 6.3 mL tetrahydrofuran solution of 0.212 g (1.31 mmol) of 1,1'-carbonyldiimidazole. After stirring overnight at room temperature, this solution was added dropwise to ethylenediamine (794 μL, 11.9 mmol). After completion of the reaction, the tetrahydrofuran was distilled off, and the resulting white solid was dissolved in water and purified by dialysis. After purification, the water was removed by lyophilization to obtain the target product (0.92 g, 92%).

[0167] Example 1. Preparation of nanosheets 1.8 g of β-cyclodextrin was dissolved in 100 mL of ion-exchanged water. 0.8 g of the α,ω-bis-aminopolyethylene glycol-block-polypropylene glycol-block-polyethylene glycol prepared in Synthesis Example 1 was added to the resulting β-cyclodextrin aqueous solution and thoroughly dissolved. The solution was stirred at room temperature for 30 days to obtain a cloudy, uncrosslinked nanosheet dispersion. Next, 10 mL of 0.1 N aqueous sodium hydroxide and 1.2 mL of epichlorohydrin were added to 90 mL of the uncrosslinked nanosheet dispersion and stirred at room temperature for 48 hours. After neutralizing the reaction solution with 10 mL of 0.1 N hydrochloric acid, the mixture was centrifuged (12,000 rpm, 10 minutes) and 90 mL of the supernatant was removed. 90 mL of ion-exchanged water was added to the remaining white solid paste to suspend the white solid. The mixture was then centrifuged again and 90 mL of the supernatant was removed. This series of steps, including adding ion-exchanged water, centrifuging, and removing the supernatant, was called the water washing process, and this water washing process was repeated four times. After four washing steps, the washing liquid became almost transparent, and after the fourth centrifugation, as much of the supernatant as possible was removed, yielding 2.3 g of nanosheet dispersion-1 (referred to as sample IT-162). 100 mg of sample IT-162 was collected and freeze-dried for 24 hours, yielding 9.8 mg of a white solid, and the nanosheet concentration in sample IT-162 was calculated to be 9.8 wt%.

[0168] Example 2. Evaluation of nanosheet degradability 1 mg of the sample IT-162 obtained in Example 1 was diluted with 1 mL of ion-exchanged water to prepare a diluted nanosheet dispersion of about 0.01 wt %.

[0169] Phase-contrast microscopy was performed, and the results are shown in Figure 7. In sample IT-162, the nanosheet crystalline structure remained even after dilution with ion-exchanged water, suggesting that the β-cyclodextrin was crosslinked.

[0170] Scanning microscope observation confirmed that diamond-shaped nanosheets with sides of 0.3-2 μm were formed (Figure 8).

[0171] Atomic force microscope observation confirmed that the thickness of the crystalline structure in sample IT-162 was 12 nm and that it was a nanosheet (Figure 9).

[0172] Example 3. Introduction of Rhodamine B 900 μL of 50 mg of rhodamine B aqueous solution (100 μg / mL) was added to the nanosheet dispersion liquid-1 (sample IT-162) obtained in Example 1, and the mixture was shaken at room temperature for 24 hours. The resulting solution was diluted 5 times with ion-exchanged water and observed under a phase-contrast microscope and a fluorescence microscope. The results are shown in Figures 10A and 10B, respectively. The crystalline structure of the nanosheets was confirmed under a phase-contrast microscope, and fluorescent coloring was observed in the crystalline structure under a fluorescence microscope, indicating that rhodamine B had been introduced into the nanosheets.

[0173] Example 4. Introduction of donepezil hydrochloride 700 μL of donepezil hydrochloride aqueous solution (500 μg / mL) was added to 500 mg of nanosheet dispersion-1 (sample IT-162) obtained in Example 1, and the mixture was shaken at room temperature for 48 hours. The donepezil hydrochloride-loaded nanosheet dispersion was centrifuged (12,000 rpm, 10 minutes), and the supernatant was collected.

[0174] The amount of donepezil hydrochloride introduced into the nanosheets was quantified by absorbance measurement using a spectrophotometer. Specifically, a concentration-absorbance calibration curve at a predetermined wavelength (λ = 320 nm) for the donepezil hydrochloride aqueous solution was prepared in advance. The concentration of donepezil hydrochloride was determined from the absorbance value of the centrifuged supernatant and the calibration curve after introduction. The decrease in concentration before and after introduction of donepezil hydrochloride was taken as the amount introduced into the nanosheets. The concentration of donepezil hydrochloride in the nanosheet dispersion before introduction was set to 304 μg / mL, taking into account dilution by the water content of the nanosheet dispersion. As a result, the concentration of donepezil hydrochloride in the nanosheet dispersion after introduction was 0 μg / mL by absorbance measurement. Therefore, 304 μg / mL of donepezil hydrochloride was introduced into 43 mg / mL of nanosheets, and the amount of donepezil hydrochloride introduced relative to the nanosheet weight was 0.70 wt%.

[0175] Example 5. Introduction of 5-fluorouracil 700 μL of a 5-fluorouracil aqueous solution (300 μg / mL) was added to 500 mg of the nanosheet dispersion-1 obtained in Example 1, and the mixture was shaken at room temperature for 48 hours. The 5-fluorouracil-loaded nanosheet dispersion was centrifuged (12,000 rpm, 10 minutes), and the supernatant was collected. Except for creating a concentration-absorbance calibration curve at a predetermined wavelength λ of 270 nm, the amount of 5-fluorouracil introduced was quantified using the same process as in Example 4. As a result, the concentration of 5-fluorouracil before introduction was 183 μg / mL, and the concentration of 5-fluorouracil after introduction was 138 μg / mL based on absorbance measurement, so 45 μg / mL of 5-fluorouracil was introduced into 43 mg / mL of nanosheets, and the amount of 5-fluorouracil introduced relative to the nanosheet weight was 0.10 wt%.

[0176] Example 6. Introduction of hydrocortisone 700 μL of a hydrocortisone aqueous solution (100 μg / mL) was added to 500 mg of the nanosheet dispersion-1 obtained in Example 1, and the mixture was shaken at room temperature for 48 hours. The hydrocortisone-loaded nanosheet dispersion was centrifuged (12,000 rpm, 10 minutes), and the supernatant was collected. Except for creating a concentration-absorbance calibration curve at a predetermined wavelength λ of 250 nm, the amount of hydrocortisone introduced was quantified using the same process as in Example 4. As a result, the concentration of hydrocortisone before introduction was 61 μg / mL, and the concentration of hydrocortisone after introduction was 26 μg / mL based on absorbance measurement, so 35 μg / mL of hydrocortisone was introduced into 43 mg / mL of nanosheets, and the amount of hydrocortisone introduced relative to the weight of the nanosheets was 0.08 wt%.

[0177] Example 7. Introduction of betamethasone 500 μL of betamethasone aqueous solution (30 μg / mL) was added to 100 mg of the nanosheet dispersion-1 obtained in Example 1, and the mixture was shaken at room temperature for 48 hours. The betamethasone-loaded nanosheet dispersion was centrifuged (12000 rpm, 10 minutes), and the supernatant was collected. Except for creating a concentration-absorbance calibration curve at a predetermined wavelength λ of 250 nm, the amount of betamethasone introduced was quantified using the same process as in Example 4. As a result, the betamethasone concentration before introduction was 25 μg / mL, and the betamethasone concentration after introduction was 17 μg / mL based on absorbance measurement, so that 8 μg / mL of betamethasone was introduced into 17 mg / mL of nanosheets, and the amount of betamethasone introduced relative to the weight of the nanosheets was 0.05 wt%.

[0178] Example 8. Menadione introduction 500 μL of a menadione aqueous solution (30 μg / mL) was added to 100 mg of the nanosheet dispersion-1 obtained in Example 1, and the mixture was shaken at room temperature for 48 hours. The menadione-introduced nanosheet dispersion was centrifuged (12,000 rpm, 10 minutes), and the supernatant was collected. Except for creating a concentration-absorbance calibration curve at a predetermined wavelength λ of 250 nm, the amount of menadione introduced was determined in the same manner as in Example 4. As a result, the menadione concentration before introduction was 25 μg / mL, and the menadione concentration after introduction was 10 μg / mL based on absorbance measurement, so 15 μg / mL of menadione was introduced into 17 mg / mL of nanosheets, and the amount of menadione introduced relative to the weight of the nanosheets was 0.09 wt%.

[0179] For Examples 4 to 8, the introduction of compounds into nanosheets is summarized in Table 1.

[0180] [Table 1]

[0181] Comparative Example 1. Preparation of nanosheets 1.8 g of β-cyclodextrin was dissolved in 100 mL of ion-exchanged water, and 0.8 g of the α,ω-bis-aminopolyethylene glycol-block-polypropylene glycol-block-polyethylene glycol prepared in Synthesis Example 1 was added to the resulting β-cyclodextrin aqueous solution and thoroughly dissolved. The solution was stirred at room temperature for 30 days to obtain a cloudy, uncrosslinked nanosheet dispersion (referred to as Sample IT-142). Next, 100 mL of Sample IT-142 was repeatedly washed with water using a centrifuge under the same conditions as in Example 1. After four washes, the white solid paste that precipitated during centrifugation disappeared, and no nanosheet crystalline structure remained (data not shown).

[0182] Comparative Example 2. Introduction of Rhodamine B To 90 mL of the uncrosslinked nanosheet dispersion (sample IT-142) obtained in Comparative Example 1, 100 μL of a rhodamine B aqueous solution (1000 μg / mL) was added and the mixture was shaken at room temperature for 24 hours. The resulting solution was observed using a phase-contrast microscope and a fluorescence microscope. The results are shown in Figures 11A and 11B, respectively. While the crystalline structure of the nanosheets could be confirmed using a phase-contrast microscope, almost no fluorescence was observed in the crystalline structure using a fluorescence microscope, suggesting that rhodamine B had not been incorporated into the nanosheets.

[0183] Example 9. Preparation of nanosheets, formation of crosslinked bodies, and introduction of molecules 1. Formation of Uncrosslinked Nanosheet Dispersion 120 mg of γ-cyclodextrin was dissolved in 1 mL of ion-exchanged water, and 30 mg of α,ω-bis-hydroxypolyethylene glycol-block-polypropylene glycol-block-polyethylene glycol was added to the resulting γ-cyclodextrin aqueous solution and thoroughly dissolved. The solution was stirred at room temperature for one day to obtain a dispersion of uncrosslinked nanosheets. This uncrosslinked nanosheet is designated γ-plu108-NS.

[0184] 2. Method for preparing crosslinked nanosheets Next, 15-crown-5-ether was added to 1 mL of the γ-plu108-NS dispersion, and then 19.2 mg / mL of adipic acid dichloride was added, and the mixture was reacted for 72 hours to obtain crude γ-plu108-NS crosslinked body.

[0185] 3. Preparation of porous nanosheets by removing the axis of nanosheets To a dispersion of unpurified γ-plu108-NS crosslinked body in 15-crown-5-ether, 1 mL of ethanol was added, followed by ion-exchanged water, to obtain an aqueous dispersion of porous γ-plu108-NS crosslinked body, which is a porous nanosheet crosslinked body from which the axial molecular PEO-PPO-PEO chains have been removed. The removal rate of the axial molecules was measured using proton nuclear magnetic resonance spectroscopy, and it was confirmed that the number of columns of cyclic molecules that did not encapsulate chain molecules (PEO-PPO-PEO) accounted for approximately 50% of the total number of columns of cyclic molecules in the nanosheet.

[0186] 4. Molecular introduction into porous nanosheets After adding and adsorbing small molecules to an aqueous dispersion of the porous γ-plu108-NS crosslinked matrix, the porous γ-plu108-NS crosslinked matrix was centrifuged to precipitate the molecules. The concentration of the small molecules in the supernatant was quantified using UV-visible spectroscopy to determine the amount of the small molecules adsorbed to the porous γ-plu108-NS crosslinked matrix. The weight ratio of the small molecules to the total weight of the small molecules and the porous γ-plu108-NS crosslinked matrix was 0.6 wt% for catechin, 0.5 wt% for coumarin, and 5.3 wt% for linoleic acid.

[0187] Example 10. Preparation of microstructure 1, formation of crosslinked body, and introduction of molecules 1. Formation of Uncrosslinked Microstructures 120 mg of γ-cyclodextrin was dissolved in 1 mL of ion-exchanged water, and 30 mg of α,ω-bis-hydroxypolypropylene glycol was added and thoroughly dissolved. The solution was stirred at room temperature for one day to obtain a dispersion of uncrosslinked microstructures. This uncrosslinked microstructure is referred to as γ-PPG4k-Plate.

[0188] 2. Method for creating a microstructure crosslinker Next, 1 mL of the γ-PPG4k-Plate dispersion was centrifuged, and the resulting supernatant was removed. 15-crown-5-ether was then added, followed by 19.2 mg / mL of adipic acid dichloride, and the mixture was allowed to react for 72 hours to obtain unpurified γ-PPG4k-Plate crosslinked material.

[0189] 3. Porous microstructure bridge by removing the axis of the microstructure bridge A 15-crown-5-ether dispersion of unpurified crosslinked γ-PPG4k-Plate was centrifuged, and the resulting supernatant was removed. 1 mL of ethanol was then added, followed by the addition of ion-exchanged water. This yielded an aqueous dispersion of crosslinked porous γ-PPG4k-Plate, a porous microstructure crosslinked body from which the PPG chains acting as the axial molecules had been removed. The removal rate of the axial molecules was measured using proton nuclear magnetic resonance spectroscopy, and it was confirmed that the number of columns of cyclic molecules that did not encapsulate chain molecules (PEO-PPO-PEO) accounted for approximately 50% of the total number of columns of cyclic molecules in the microstructure.

[0190] 4. Molecular introduction into porous microstructure bridge Low molecular weight compounds were added to an aqueous dispersion of crosslinked porous γ-PPG4k-plates and allowed to adsorb. The crosslinked porous γ-PPG4k-plates were then centrifuged to sediment. The concentration of the low molecular weight compounds in the resulting supernatant was quantified using UV-visible spectroscopy to determine the amount of adsorption of the low molecular weight compounds onto the crosslinked porous γ-PPG4k-plates. The weight ratio of the low molecular weight compounds to the total weight of the low molecular weight compounds and crosslinked porous γ-PPG4k-plates was 0.7 wt% for catechin, 0.6 wt% for coumarin, and 0.9 wt% for linoleic acid. However, biotin, rhodamine B, nicotinic acid, and dorzolamide were not incorporated.

[0191] Example 11. Preparation of microstructure 2, formation of crosslinked body, and purification 1. Formation of Uncrosslinked Microstructures 120 mg of γ-cyclodextrin was dissolved in 1 mL of ion-exchanged water, and 30 mg of linoleic acid was added to the resulting γ-cyclodextrin aqueous solution and thoroughly dissolved. The solution was stirred at room temperature for one day to obtain a dispersion of uncrosslinked microstructures. This uncrosslinked microstructure is referred to as γ-Lino-Plate.

[0192] 2. Method for creating a microstructure crosslinker Next, 15-crown-5-ether was added to 1 mL of the γ-Lino-Plate dispersion, and then 19.2 mg / mL of adipic acid dichloride was added, and the mixture was reacted for 72 hours to obtain a crosslinked γ-Lino-Plate.

[0193] 3. Purification of Microstructure Crosslinks The 15-crown-5-ether dispersion of the unpurified crosslinked γ-Lino-Plate was centrifuged, the resulting supernatant was removed, and ion-exchanged water was added to obtain a purified aqueous dispersion of the crosslinked γ-Lino-Plate. [Explanation of symbols]

[0194] 10...cyclic molecule, 20...chain polymer as chain molecule, 30...pseudopolyrotaxane and / or polyrotaxane, 40, 42, 44...nanosheet as nano- or microstructure, 40'...nano- or microstructure.

Claims

1. A nano- or microstructure comprising a plurality of cyclic molecules each having an opening and a plurality of chain molecules, wherein each of the plurality of chain molecules is skewered and included in some of the plurality of cyclic molecules to form a plurality of pseudo-polyrotaxanes and / or polyrotaxanes, A nano- or microstructure in which all or some of the adjacent cyclic molecules in the nano- or microstructure are cross-linked to each other, the plurality of cyclic molecules arranged in series in the nano- or microstructure form columns, and the number of columns that do not encapsulate chain molecules exceeds 10% of the total number of columns in the nano- or microstructure.

2. 2. The nano- or microstructure according to claim 1, wherein 10% or more of the total number of cyclic molecules in the nano- or microstructure are crosslinked.

3. 2. The nano- or microstructure according to claim 1, wherein each of the chain molecules in the plurality of pseudopolyrotaxanes and / or polyrotaxanes has a non-ionizable group that does not ionize in water or an aqueous solution at both ends thereof or within a range of 1 to 10 monomer units from both ends.

4. 2. The nano- or microstructure according to claim 1, wherein each of the chain molecules in the plurality of pseudopolyrotaxanes and / or polyrotaxanes has an ionizable group that ionizes in water or an aqueous solution at both ends thereof or within a range of 1 to 10 monomer units from both ends.

5. The nano- or microstructure according to claim 1, wherein the chain molecule has first and second regions inward from both ends of the chain molecule where the cyclic molecules are not present, and the lengths of the first and second regions are 0.5 to 100 nm.

6. 2. The nano- or microstructure according to claim 1, wherein the cyclic molecule is selected from the group consisting of α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, crown ether, pillararene, calixarene, cyclophane, cucurbituril, and derivatives thereof.

7. The nano- or microstructure according to claim 1 , wherein a substance is enclosed in the opening.

8. The nano- or microstructure according to claim 1 , wherein the microstructure is a nanosheet.

9. An adsorbent for a substance comprising the nano- or microstructure according to any one of claims 1 to 7.

10. A pharmaceutical comprising the nano- or microstructure according to any one of claims 1 to 7.

11. A food product containing the nano- or microstructure according to any one of claims 1 to 7.

12. A method for manufacturing a nano- or micro-structure, comprising the steps of: a step of crosslinking a nano- or microstructure comprising a plurality of pseudo-polyrotaxanes and / or polyrotaxanes each comprising a plurality of cyclic molecules each having an opening and a plurality of chain molecules, wherein each of the plurality of chain molecules is skewered and enclosed within some of the plurality of cyclic molecules, to obtain a nano- or microstructure in which all or some of adjacent cyclic molecules are crosslinked to each other; and removing some or all of the chain molecules that are skewered and included in some of the cyclic molecules.

Images